742102-31-4

Upstream product

• 1458-01-1 3,5-diamino-6-chloro-pyrazine-2-carboxylic acid methyl ester 
• 24424-99-5 di-tert-butyl dicarbonate 
• 1080018-69-4 3,5-diamino-6-chloropyrazine-2-carboxylic acid lithium salt 
• 173998-77-1 tert-butyl [amino(methylthio)methylene]carbamate 
• 76942-92-2 methyl 3,5-diamino-6-chloropyrazine-2-carbonylcarbamimidothioate hydroiodic acid salt 
• 1122-58-3 dmap 

Downstream Products

• 1080018-66-1 tert-butyl (1,1'-(1,4-phenylene)bis(oxomethylene)bis(piperidine-4,1-diyl))bis(azanediyl)bis((3,5-diamino-6-chloropyrazine-2-carboxamido)methan-1-yl-1-ylidene)dicarbamate 

Relevant academic research and scientific papers

COMPOUNDS FOR TREATMENT OF CYSTIC FIBROSIS

Described herein are compounds, compositions, and methods of their use for the treatment of cystic fibrosis.

Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases

The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES

The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

Organic Compounds

A compound of Formula I in free or salt or solvate form, where R1, R2, R3, R4, R5, R6, R7, R8, R9, R10 and R11 have the meanings as indicated in the specification, is useful for treating diseases which respond to the blockade of the epithelial sodium channel. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.

ORGANIC COMPOUNDS

A compound of formula (I), or tautomers, or stereoisomers, or solvates, or pharmaceutically acceptable salts thereof, wherein M1, M2, L1, L2, W1, W2, X1, X2, Y1/

ORGANIC COMPOUNDS

A compound of formula (I) or tautomers, or stereoisomers, or solvates, or pharmaceutically acceptable salts thereof, wherein M1, M1, L1, L2, W1, W2, X1, X2, Y1, Y2, A, R5 and R5a are as defined herein for the for treatment of conditions mediated by the blockade of an epithelial sodium channel, particularly an inflammatory or allergic condition.

Sodium channel blockers

The present invention relates to sodium channel blockers. The present invention also includes a variety of methods of treatment using these inventive sodium channel blockers.